Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction: ALPS-AMI study

Circulation Journal

Volumn 79, Issue 1, 2014, Pages 161-168

  Izawa, Atsushi ^a   Kashima, Yuichiro ^a   Miura, Takashi ^a   Ebisawa, Soichiro ^a   Kitabayashi, Hiroshi ^b   Yamamoto, Hiroaki ^c   Sakurai, Shunpei ^d   Kagoshima, Mitsuru ^e   Tomita, Takeshi ^a   Miyashita, Yusuke ^a   Koyama, Jun ^a   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ina General Hospital   (Japan)

^c Nagano Chuo Hospital   (Japan)

^d Specified Medical Corporation Jisenkai Aizawa Hospital   (Japan)

^e Joetsu General Hospital   (Japan)

Author keywords

Acute myocardial infarction; Secondary prevention; Statin

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; LIPID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROPHILICITY; INCIDENCE; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; BLOOD; CARDIOVASCULAR DISEASES; CHEMICAL PHENOMENA; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HYPERCHOLESTEROLEMIA; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATIENT ATTITUDE; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; SOLUBILITY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

AGED; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPERCHOLESTEROLEMIA; JAPAN; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT ACCEPTANCE OF HEALTH CARE; PRAVASTATIN; RECURRENCE; SINGLE-BLIND METHOD; SOLUBILITY;

EID: 84925458587     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0877     Document Type: Article

References (42)

1. Jones K, Saxon L, Cunningham W, Adams P, Guideline Development Group. Secondary prevention for patients after a myocardial infarction: Summary of updated NICE guidance. BMJ 2013; 347: f6544.
2. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58: 2432-2446.
3. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
4. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol 2010; 21: 298-304.
5. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-925.
6. Oh J, Kang SM, Hong N, Youn JC, Park S, Lee SH, et al. Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Circ J 2014; 78: 2447-2454.
7. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
8. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI. Circ J 2007; 71: 1348-1353.
9. Steffens S, Mach F. Drug insight: Immunomodulatory effects of statins: Potential benefits for renal patients? Nat Clin Pract Nephrol 2006; 2: 378-387.
10. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012; 60: 1231-1238.
11. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: Weighing the evidence. J Am Coll Cardiol 2012; 60: 875-881.
12. Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and reninangiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014; 78: 281-287.
13. Sakuma I. What type of statin and what level of low-density lipoprotein cholesterol should be appropriate for secondary prevention for Japanese patients with coronary artery disease? Circ J 2012; 76: 1324-1325.
14. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
15. Kashima Y, Izawa A, Aizawa K, Koshikawa M, Kasai H, Tomita T, et al. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. J Cardiol 2009; 54: 76-79.
16. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
17. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome study). J Am Coll Cardiol 2009; 54: 293-302.
18. Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, et al. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy: The extended JAPAN-ACS study. Circ J 2012; 76: 825-832.
19. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the INTERHEART Study. J Am Coll Cardiol 2009; 53: 244-253.
20. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol 2011; 58: 1664-1671.
21. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
22. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
23. Okada K, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, et al. Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: Sub-analysis of the TWINS study. Circ J 2012; 76: 1197-1202.
24. Ray KK, Cannon CP. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1425-1433.
25. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: A LDL-associated action or one more pleiotropic effect of statins? Atherosclerosis 2010; 213: 8-20.
26. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576-583.
27. Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets TNT study). Am J Cardiol 2012; 109: 1761-1766.
28. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206: 512-517.
29. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 2009; 20: 2546-2555.
30. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005; 19: 117-125.
31. Ichihara K, Satoh K, Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J Cardiovasc Pharmacol 1993; 22: 852-856.
32. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000; 35: 256-262.
33. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1609-1614.
34. Kim MC, Ahn Y, Jang SY, Cho KH, Hwang SH, Lee MG, et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J Intern Med 2011; 26: 294-303.
35. Hirayama S, Nakagawa S, Soda S, Kamimura Y, Nishioka E, Ueno T, et al. Ezetimibe decreases serum oxidized cholesterol without impairing bile acid synthesis in Japanese hypercholesterolemic patients. Atherosclerosis 2013; 230: 48-51.
36. Okada K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, et al. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 2012; 224: 454-456.
37. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: Results of a pilot study. J Cardiovasc Pharmacol Ther 2013; 18: 5-12.
38. Lin CF, Gau CS, Wu FL, Hsiao FY, Bai CH, Shen LJ. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: A 3-year population-based retrospective cohort study in Taiwan. Clin Ther 2011; 33: 1120-1131.
39. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.
40. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-2122.
41. Ijioma N, Robinson JG. Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Rev Cardiovasc Ther 2011; 9: 131-145.
42. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials. Lancet 2010; 375: 735-742.